Today, Regeneron Pharmaceuticals Inc. (REGN) Given a $440.00 Price Target at JPMorgan Chase & Co.

Today, Regeneron Pharmaceuticals Inc. (REGN) Given a $440.00 Price Target at JPMorgan Chase & Co.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) received a $440.00 target price from equities researchers at JPMorgan Chase & Co. in a research report issued to clients and investors on Sunday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s target price indicates a potential upside of 10.51% from the company’s previous close.

REGN has been the subject of a number of other reports. Cowen and Company reaffirmed a “hold” rating and issued a $430.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 5th. Roth Capital reaffirmed a “buy” rating and issued a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, September 23rd. Vetr downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $422.08 price objective for the company. in a research report on Wednesday, July 27th. Piper Jaffray Cos. set a $447.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, October 13th. Finally, RBC Capital Markets reaffirmed an “outperform” rating and issued a $648.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 4th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $468.87.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.06% during midday trading on Friday, reaching $398.16. 282,742 shares of the company traded hands. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $566.52. The firm has a market capitalization of $41233.05 billion, a PE ratio of 58.13 and a beta of 1.79. The company has a 50-day moving average of $381.52 and a 200 day moving average of $389.29.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 EPS for the quarter, topping the consensus estimate of $2.73 by $0.40. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The company earned $1.22 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the previous year, the firm posted $3.47 earnings per share. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals will post $11.73 earnings per share for the current year.

In other news, Director Joseph L. Goldstein sold 2,125 shares of the firm’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $450.00, for a total transaction of $956,250.00. Following the sale, the director now owns 15,125 shares in the company, valued at approximately $6,806,250. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Arthur F. Ryan sold 2,000 shares of the firm’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $429.34, for a total transaction of $858,680.00. Following the sale, the director now owns 36,500 shares in the company, valued at approximately $15,670,910. The disclosure for this sale can be found here. 10.40% of the stock is currently owned by company insiders.

Several hedge funds have recently bought and sold shares of REGN. Piedmont Investment Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at $6,902,000. LPL Financial LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at $1,233,000. Credit Suisse AG boosted its stake in Regeneron Pharmaceuticals by 2.5% in the third quarter. Credit Suisse AG now owns 258,909 shares of the biopharmaceutical company’s stock valued at $104,086,000 after buying an additional 6,236 shares during the period. Ameritas Investment Partners Inc. boosted its stake in Regeneron Pharmaceuticals by 8.9% in the third quarter. Ameritas Investment Partners Inc. now owns 3,661 shares of the biopharmaceutical company’s stock valued at $1,472,000 after buying an additional 298 shares during the period. Finally, Candriam Luxembourg S.C.A. boosted its stake in Regeneron Pharmaceuticals by 11.7% in the third quarter. Candriam Luxembourg S.C.A. now owns 106,210 shares of the biopharmaceutical company’s stock valued at $42,699,000 after buying an additional 11,106 shares during the period. Hedge funds and other institutional investors own 68.45% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Related posts

Leave a Comment